2018 MASCC/ISOO Annual Meeting Study Group Workshops

Workshops:  2019  |  2018  |  2017  |  2016  |   2015  |  2014  |  2013  |  2012  |  2011 

Thursday June 28, 2018  •  Vienna, Austria
Powerpoint presentation files from the meeting have been converted to PDF to reduce file size.

Workshop 1: 10th Mucositis Research Workshop: Mucositis Study Design: What Do We Need to Know?
The overall goal of this workshop, presented by the Mucositis Study Group, was to bring together basic, translational, and clinical researchers in an informal setting to advance the understanding of mucositis mechanisms and management. This year’s program, led by Sharon Elad, focused on the design of mucositis studies. The workshop has the following objectives:

  • To present the latest state of the science in mucositis research;
  • To facilitate exchange of knowledge between experts and young researchers from all over the world;
  • To provide an opportunity for young investigators to present their work to an expert audience for specialized feedback and research advice;
  • To provide an opportunity for face-to-face discussions regarding collaborative research and development of international research networks;
  • To develop links with multidisciplinary teams to pursue new research and funding opportunities.

The Bile Acid Agonist TGR5 Induces Intestinal Growth and Ameliorates Intestinal Mucositis in Mice  - Hannelouise Kissow, Denmark 
Consistency and Mechanistic Implications of Genomic Risk Prediction Studies for Cancer Regimen-Related Mucosal Injury: A Systematic Review   - Petra Bachour, USA 
Incidence of Other Toxicities in Patients with Severe Gastrointestinal Toxicity and Relationship to Comorbidities Following 5-Fluorouracil (5-FU) Treatment - Joanne Bowen, Australia 
Oral Mucositis in Stem Cell Transplant Patients: Epidemiology and Economics  - Karin Berger, Germany 
Prophylactic Probiotics for Cancer Therapy-Induced Diarrhea: A Meta-Analysis  - Hannah Wardill, Australia 
Evidence-based Confounding Factors in the Assessment of Oral Mucositis - Paolo Bossi, Italy 
Necessary Elements for Clinical Mucositis Research of FDA-Regulated Products - Joan Adamo, USA 

Workshop 2: Update and New Developments in Supportive Care of Patients with Chemotherapy-Induced Alopecia
Over the past two years, new data has emerged concerning the use of scalp-cooling devices to prevent chemotherapy-induced alopecia. The purpose of this workshop was to provide an update on new developments and recommendations for the supportive care management of chemotherapy-induced alopecia. The workshop was presented by the Skin Toxicities Study Group and was led by Jennifer Choi and Mario Lacouture.
Introduction - Mario Lacouture, USA
Basic Mechanisms Of Chemotherapy-Induced Alopecia - Ralf Paus, USA
Scalp Cooling Worldwide - Corina van den Hurk, The Netherlands
Scalp Cooling to Prevent Chemotherapy-Induced Alopecia: The US Experience - Julie Nangia, USA
Scalp Cooling in the US - Hope Rugo, USA
Eyebrow and Eyelash Chemotherapy-Induced Alopecia - Frances Boyle, Australia
Permanent Chemotherapy-Induced Alopecia - Juhee Cho, Republic of Korea
Endocrine Therapy-Induced Alopecia - Mario Lacouture, USA
Nursing Implications in Scalp Cooling - Annie Young, United Kingdom
Guidance for the management of chemotherapy induced hair loss

Workshop 3: What Does the Future Hold? Prognostication in Advanced Cancer and Clinical Decision Making
Patients with advanced cancer often want to know how long they will live and what they can expect at the end of life. Indeed, the ability to estimate prognosis accurately and communicate this information sensitively is one of the most important clinical skills. This comprehensive workshop was designed to provide an up-to-date overview of the latest literature and advances in the science and art of prognostication. It included discussion of survival prediction for both adults and children, a review of established and novel prognostic factors, and presentation of the latest prognostic models and websites. It also addressed prediction of survival and other outcomes and a summary of communication techniques and tools. The panel of experts in prognostication discussed prognostication research methods and made predictions on where this field is going. The workshop represented a collaboration between the Education, Palliative Care, Nutrition & Cachexia, and Pediatrics Study Groups and was led by David Hui, Marianne van de Wetering, Paz Fernández-Ortega, and Egidio Del Fabbro.
Prognostication in Advanced Adult Cancers: An Evidence-Based Update  - Carlos Paiva, Brazil
Prognostication in Advanced Paediatric Malignancies  - Marianne van de Wetering, The Netherlands
Predictive/Prognostic Value of Anorexia-Cachexia  - Egidio del Fabbro, USA
Predictive Models for Cancer Treatment Side Effects  - Christopher Steer, Australia
What Do Patients Want to Know About the Future?  - Paz Fernández - Ortega, Spain
Future Research in Prognostication: Maximizing Patient Outcomes  - Masanori Mori, Japan
Predicting the Unpredictable: Moving Forward with Prognostication Research  - David Hui, USA

Workshop 4: Update and New Developments in Supportive Care of Patients Undergoing Immunotherapy
This workshop focused on advances in the field of immuno-oncology and the management of related side effects. Over the past two years, new data have emerged concerning the use of immune checkpoint inhibitors in combination with chemotherapy, other checkpoint inhibitors, immune-modulatory molecules, and oncolytic viruses. The purpose of this workshop was to provide an update on new developments and recommendations on the supportive care management of patients with immunotherapy-related adverse events. The workshop was presented jointly by the Neutropenia, Infection and Myelosuppression Study Group and the Skin Toxicities Study Group, and was led by Jean Klastersky, Mario Lacouture, Jennifer Choi, and Bernardo Rapoport.
Basic Mechanism of Immunotherapy  - Ada Blidner, Argentina
Update on the Recent Developments of Checkpoint Inhibitors  - Bernardo Rapoport, South Africa
Immune-Related Adverse Events (irAEs): Dermatological  - Mario Lacouture, USA
Immune-Related Adverse Events (irAEs): GI and Hepatic  - Michael Dougan, USA
Immune-Related Adverse Events (irAEs): Renal and Endocrine  - Jean Klastersky, Belgium
Update on Recommendations and Guidelines  - Jennifer Choi, USA

Workshop 5: Challenging Communications in Oncology
Communication is fundamental to the practice of oncology, but can often be challenging for healthcare professionals — as well as for patients and their carers. The aim of this workshop was to emphasize the positive effects of "good" communication, to highlight the negative effects of "poor" communication, and to provide the attendees with advice and guidance for undertaking difficult conversations. The mixed format included lectures, panel discussions, and audience participation. The workshop represented a collaboration between the Psychosocial Study Group and the Palliative Care Study Group, and was led by Andrew Davies, Lidia Schapira, Penny Schofield, and Greg Crawford.
Introduction by Workshop Chairs 
Communication: The Good, the Bad, and the Ugly  - Gregory Crawford, Australia
What about Carers?  - Youngmee Kim, USA 
How Should We Explain Response to Cancer Treatment?  - Andrew Davies, United Kingdom
Dealing with Uncertainty (Response to Cancer Treatment)  - Lidia Schapira, USA
Dealing with Transition (From Active Cancer Treatment to Palliative Care Alone)  - Penelope Schofield, Australia